The continued expansion of biosimilars and complex biologics will further democratise access to cutting-edge treatments worldwide, while the rapid growth of CRDMOs will establish India as a preferred destination for high-value outsourcing in an era of supply-chain reconfiguration.'' Domestic pharma is scaling up R&D, particularly for advanced biologics, GLs, antibody-drug conjugate, cell and gene therapies, and pivoting from simple to complex generics, according to Srikanth Mahadevan, director, Deloitte India.Further, "private equity interest will remain a dominant theme for healthcare providers, particularly hospitals, medical services and digital health
But there's a quieter, emerging trend gaining traction among physicians and health-optimizing individuals alike: microdosing GLP-1 medications
doi: 10.2337/dc25-0241
Women going through menopause typically experience a drop in bone density, increasing the risk of osteoporosis and bone fractures
When made according to federal laws, compounded drugs do not require FDA approval and are exempt from undergoing safety, effectiveness, or manufacturing reviews
Balch B
